West Pharmaceutical Services, Inc. $WST Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC raised its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 156,895 shares of the medical instruments supplier’s stock after buying an additional 10,023 shares during the period. Hsbc Holdings PLC’s holdings in West Pharmaceutical Services were worth $39,262,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of WST. Norges Bank purchased a new stake in shares of West Pharmaceutical Services during the 4th quarter worth about $272,041,000. Generation Investment Management LLP increased its stake in shares of West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after purchasing an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after purchasing an additional 473,547 shares in the last quarter. Steadfast Capital Management LP acquired a new position in West Pharmaceutical Services in the 3rd quarter worth about $123,667,000. Finally, AQR Capital Management LLC raised its holdings in West Pharmaceutical Services by 420.1% in the 3rd quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock worth $142,949,000 after purchasing an additional 440,929 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the company. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Morgan Stanley increased their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. KeyCorp boosted their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, BNP Paribas Exane initiated coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $363.17.

Insider Transactions at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by corporate insiders.

West Pharmaceutical Services Stock Performance

Shares of NYSE:WST opened at $353.10 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. West Pharmaceutical Services, Inc. has a 1 year low of $208.71 and a 1 year high of $367.66. The firm has a market capitalization of $24.95 billion, a PE ratio of 47.21, a P/E/G ratio of 2.90 and a beta of 1.16. The business’s 50 day moving average price is $333.33 and its 200-day moving average price is $285.41.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.67 million. During the same quarter last year, the firm posted $1.45 EPS. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, equities research analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.